We're in the hot pipeline asset, now let's just get that darn efficacy. I recall that management has always been consistent in talking about the platform - SORT1+ --as something that will (if it works) make existing drugs much more effective and enhance overall performance of many drugs. This article also makes it seem like Novartis is the big pharma that needs some help in the area
...more